Arginine demethylation of Serine/Arginine‐rich splicing factor 1 enhances miRNA enrichment in small extracellular vesicles derived from pancreatic ductal adenocarcinoma cells
- 6 January 2025
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 39 (1) , e70287
Abstract
Small extracellular vesicles (sEVs) are enriched in certain miRNAs, impacting the progression of pancreatic ductal adenocarcinoma (PDAC). The mechanisms involved in the selective sEV miRNA enrichment remain to be elucidated. We recently reported that Serine/Arginine‐rich splicing factor 1 (SRSF1) regulates selective sEV miRNA enrichment in PDAC cells. SRSF1 is an onco‐protein that is overexpressed in PDAC, and its function is dictated by posttranslational modifications such as phosphorylation and arginine methylation. The objective of this study was to examine the role of phosphorylation and arginine methylation in SRSF1‐mediated sEV miRNA enrichment in PDAC cells. Treatment of PDAC cells with the protein arginine methyltransferase inhibitors AMI‐5 and EPZ015666, but not with the phosphorylation inhibitor SRPIN340, selectively enhanced the level of sEV miR‐1246, a miRNA known to be highly enriched in PDAC sEVs. Consistently, overexpression of the mutant SRSF1 with the three arginine residues R93, R97, and R109 being replaced with lysinaugmented sEV miR‐1246 levels in both wild‐type and SRSF1‐knockdown PANC‐1 cells. Interestingly, the binding of SRSF1 to miR‐1246 was significantly reduced in PDAC cells overexpressing the mutant SRSF1, which was further confirmed using purified wild‐type and the mutant SRSF1 proteins. We demonstrate that arginine demethylation of SRSF1 reduces SRSF1‐miRNA binding in PDAC cells and enhances selective sEV miRNA enrichment, providing novel insight into SRSF1‐mediated sEV miRNA enrichment in PDAC cells and opening up new avenues of investigation on the biology and function of extracellular vesicles in PDAC.Keywords
Funding Information
- Congressionally Directed Medical Research Programs (W81XWH‐22‐1‐0317)
- National Institute of General Medical Sciences (P30GM145423)
- Presbyterian Health Foundation
- National Cancer Institute (P30CA225520)
This publication has 51 references indexed in Scilit:
- Targeting PRMT1-mediated SRSF1 methylation to suppress oncogenic exon inclusion events and breast tumorigenesisCell Reports, 2023
- Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replicationJournal of Biological Chemistry, 2021
- Exploring interactions between extracellular vesicles and cells for innovative drug delivery system designAdvanced Drug Delivery Reviews, 2021
- Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses?Cancer Letters, 2020
- SRSF1 and RBM4 differentially modulate the oncogenic effect of HIF-1α in lung cancer cells through alternative splicing mechanismBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2019
- SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistanceEBioMedicine, 2018
- Octamer 4/microRNA‐1246 signaling axis drives Wnt/β‐catenin activation in liver cancer stem cellsHepatology, 2016
- Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and UptakeCellular and Molecular Neurobiology, 2016
- Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancerLung Cancer, 2016
- Arginine methylation of the cellular nucleic acid binding protein does not affect its subcellular localization but impedes RNA bindingFEBS Letters, 2014